Direct-Acting Antiviral Hepatitis C Therapy in Patients with Chronic Renal Failure

The prevalence of hepatitis C virus (HCV) infection is estimated at 3 % in the global population, it is higher in patients on hemodialysis, the treatment of viral hepatitis C has increased with appearance of new antiviral molecules specifically targeting the virus that has revolutionized the therapeutic response Materials and methods this is a retrospective study from 2015 to February 2018 in the service of hepato-gastroenterology, University Hospital Mohamed VI, Marrakech including 33 hemodialysis patients or follow-up for renal insufficiency not dialyzed and put on treatment by sofosbuvir400mg / day in association with daclatasvir 60mg / d including 2 patients with severe renal insufficiency (creatinine clearance